

# CONTENTS

<b>Contributors</b>	<b>xiii</b>
<b>Foreword</b>	<b>xv</b>
<b>Preface</b>	<b>xvii</b>
<b>Preface to the First Edition</b>	<b>xix</b>
<b>Acknowledgments</b>	<b>xxi</b>
<b>Organization of the Book</b>	<b>xxiii</b>
<b>User Agreement</b>	<b>xxv</b>

<b>PART I</b>	
<b>TRANSFORMING PROTEINS AND GENES INTO DRUGS—THE SCIENCE AND THE ART</b>	<b>1</b>
<b>1 Introduction to Biopharmaceuticals</b>	<b>3</b>
Abstract	3
1.1 Background and Significance	4
1.2 Translation of Biotechnology for Developing Biopharmaceuticals	7
1.3 Historical Perspective of Pharmaceutical Biotechnology	8
1.4 Distinctions between Chemical Drugs Versus Biopharmaceuticals	8
1.5 Summary	10
<b>2 Distinctions of Biologic Versus Small Molecule Platforms in Drug Development</b>	<b>13</b>
Abstract	13
2.1 Introduction	14
2.2 Transforming New Molecules into Drugs: The Drug Development Process	14
2.3 Key Differences between Biotechnology and Chemical Products	16
2.4 Current Trends in Drug Development	18
2.5 Summary	22
<b>3 Financing Biologic Drug Development</b>	<b>23</b>
Abstract	23
3.1 Introduction	24
3.2 The Role of the Orphan Drug Act	27
3.3 Clinical Leverage Strategy in Accelerating Drug Development	30
3.4 Therapeutic Target Considerations	32
3.5 Evolving Trends	34
3.6 Summary	36

<b>4</b>	<b>Application of Biotechnology in Drug Discovery and Early Development</b>	<b>39</b>
	Abstract	39
	4.1 Introduction	40
	4.2 Data Mining, Molecular Cloning, and Characterization	40
	4.3 Optimization of Cell Expression Systems and Product Yield	50
	4.4 Molecular Optimization	51
	4.5 Proteins and Genes as Targets for Drug Discovery and Development	56
	4.6 Summary	58
<b>5</b>	<b>Large-Scale Production of Recombinant Proteins</b>	<b>63</b>
	Abstract	63
	5.1 Introduction	64
	5.2 Yield Optimization in Genetic Constructs and Host Cells	65
	5.3 Large-Scale Cultivation of Host Cells	66
	5.4 Downstream Processing and Purification	70
	5.5 Quality Assurance and Quality Control	75
	5.6 Summary	77
<b>6</b>	<b>Clinical Pharmacology, Toxicology, and Therapeutic Dosage and Response</b>	<b>79</b>
	Abstract	79
	6.1 Introduction	80
	6.2 Clinical Pharmacology and Toxicology	80
	6.3 Dose and Therapeutic Response	95
	6.4 Dosage Form and Route of Administration	97
	6.5 Summary	99
<b>7</b>	<b>Clinical Evaluation and Regulatory Approval and Enforcement of Biopharmaceuticals</b>	<b>103</b>
	Abstract	103
	7.1 Introduction: Biologic Drug Development and Approval	104
	7.2 Licensing of Biological Products	104
	7.3 Preclinical and Clinical Testing	107
	7.4 FDA Review and Approval Process	114
	7.5 Regulatory Enforcement	118
	7.6 Globalization of Drug Approval ( <i>Chien*</i> )	118
	7.7 Summary	122
<b>8</b>	<b>Pharmacoeconomics and Drug Pricing (<i>Garrison*</i>)</b>	<b>125</b>
	Abstract	125
	8.1 Introduction: Pharmacoeconomics	126
	8.2 Cost-Effectiveness: Assessing the Value of Biopharmaceuticals	126
	8.3 The Cost of Developing Biopharmaceuticals	128
	8.4 Pricing Biopharmaceuticals	131
	8.5 Drug Development Incentives	133
	8.6 Economics of Biosimilars	133
	8.7 Economic Impact of Personalized Medicine	134
	8.8 Summary and Future Challenges	135

<b>PART II</b>	
<b>THERAPEUTIC AND CLINICAL APPLICATIONS OF BIOPHARMACEUTICALS—</b>	
<b>PROTEINS AND NUCLEIC ACIDS</b>	<b>137</b>
<b>9 Antibodies and Derivatives</b>	<b>139</b>
Abstract	139
Section One	140
9.1 Molecular Characteristics and Therapeutic Applications	140
9.1.1 Introduction	140
9.1.2 Historical Perspective—Discovery, Classification, Biodistribution, and Physiological Characteristics of Antibody Molecules	140
9.1.3 Gamma Globulin and Hyperimmune Globulin	144
9.1.4 Monoclonal Antibodies—From Mouse, Mouse-Human Chimeric, Humanized, to Human Monoclonal Antibodies	145
9.1.5 Antibody Derivatives	147
9.1.6 Disposition of Antibodies	149
9.1.7 Extravascular Tissue Penetration	155
9.1.8 Mechanisms of Antibody Bioactivities	156
9.1.9 Antibody Conjugates	156
9.1.10 Antibodies and Derivatives in Development	158
9.1.11 Summary	159
Section Two	162
9.2 Antibodies and Derivatives Monographs List	162
9.3 Antibodies and Derivatives Monographs	163
<b>10 Hematopoietic Growth and Coagulation Factors</b>	<b>211</b>
Abstract	211
Section One	212
10.1 Molecular Characteristics and Therapeutic Applications	212
10.1.1 Introduction	212
10.1.2 Hematopoietic Growth and Coagulation Factors	212
10.1.3 Therapeutic Use of Hematopoietic Growth Factors ( <i>Molineux, Elliott*</i> )	218
10.1.4 Therapeutic Use of Coagulation and Anticoagulation Factors	225
10.1.5 Summary	229
Section Two	231
10.2 Hematopoietic Growth and Coagulation Factors List	231
10.3 Hematopoietic Growth and Coagulation Factors Monographs	231
<b>11 Cytokines and Interferons</b>	<b>251</b>
Abstract	251
Section One	252
11.1 Molecular Characteristics and Therapeutic Applications	252
11.1.1 Introduction	252
11.1.2 Interleukins as Immunotherapeutics	252
11.1.3 Interferon Biology and Cancer Therapy ( <i>Tiu, Koon, Borden*</i> )	256
11.1.4 Interferons as Antiviral Therapy	271
11.1.5 Interferons in Multiple Sclerosis	275
11.1.6 Summary	280

Section Two	288
11.2 Cytokines and Interferons Monographs List	288
11.3 Cytokines and Interferons Monographs	288
<b>12 Hormones</b>	<b>307</b>
Abstract	307
Section One	308
12.1 Molecular Characteristics and Therapeutic Applications	308
12.1.1 Introduction	308
12.1.2 Peptide Hormones and Clinical Significance	308
12.1.3 Therapeutic Application of Recombinant and Synthetic Hormones	309
12.1.4 Summary	318
Section Two	320
12.2 Hormones Monographs List	320
12.3 Hormones Monographs	320
<b>13 Enzymes</b>	<b>357</b>
Abstract	357
Section One	358
13.1 Molecular Characteristics and Therapeutic Applications	358
13.1.1 Introduction	358
13.1.2 Enzyme Replacement Therapy	359
13.1.3 Enzymes as Therapeutic Agents	365
13.1.4 Summary and Future Prospects	368
Section Two	370
13.2 Enzymes Monographs List	370
13.3 Enzymes Monographs	370
<b>14 Vaccines (<i>Hu, Ho*</i>)</b>	<b>389</b>
Abstract	389
Section One	390
14.1 Molecular Characteristics and Therapeutic Applications	390
14.1.1 Vaccines and Their Impact on Human Health	390
14.1.2 How Vaccines Work: Interplay Among Immune System, Diseases, and Vaccines	393
14.1.3 Traditional Vaccine Approaches	394
14.1.4 Subcellular and Recombinant Subunit Vaccines	395
14.1.5 Vaccine Adjuvants	398
14.1.6 Mode and Route of Vaccine Delivery	400
14.1.7 Future Directions	403
14.1.8 Summary	405
Section Two	409
14.2 Vaccines Monographs List	409
14.3 Vaccines Monographs	409
<b>15 Other Biopharmaceutical Products</b>	<b>417</b>
Abstract	417
15.1 Other Biopharmaceutical Products Monographs List	418
15.2 Other Biopharmaceutical Products Monographs	418

<b>PART III</b>	
<b>FUTURE DIRECTIONS</b>	<b>425</b>
<b>16 Advanced Drug Delivery</b>	<b>427</b>
Abstract	427
16.1 Introduction	428
16.2 Drug Therapeutic Index and Clinical Impact	429
16.3 Routes of Therapeutic Protein Administration	430
16.4 Physiological and Mechanistic Approaches	436
16.5 Approaches Using Devices	458
16.6 Molecular Approaches	460
16.7 Summary	465
<b>17 Advances in Personalized Medicine: Pharmacogenetics in Drug Therapy</b>	<b>471</b>
Abstract	471
17.1 Introduction to Interindividual Variation	472
17.2 Historical Perspective on Pharmacogenetics in Drug Safety and Efficacy	473
17.3 Pharmacogenetics in Drug Disposition and Pharmacokinetics	478
17.4 Pharmacogenetics in Drug Effects and Pharmacodynamics	483
17.5 Individualized Gene-Based Medicine: A Mixed Blessing	487
17.6 Current and Future Prospects of Pharmacogenetics	490
17.7 Summary	492
<b>18 Gene and Cell Therapy</b>	<b>495</b>
Abstract	495
18.1 Overview	496
18.2 General Strategies in Gene and Cell Therapy	499
18.3 Gene and Cell Therapy for Select Medical Conditions	501
18.4 Gene Therapy Research, Development, and Clinical Use ( <i>Sullivan*</i> )	506
18.5 Stem Cells in Regenerative Medicine and Diagnostics ( <i>Kelly*</i> )	509
18.6 Summary	513
<b>19 Integration of Discovery and Development: The Role of Genomics, Proteomics, and Metabolomics</b>	<b>517</b>
Abstract	517
19.1 Overview	518
19.2 Integration of Discovery and Development of Therapeutic Candidates	520
19.3 Genomics: The First Link between Sequences and Drug Targets	521
19.4 Proteomics: From Sequences to Functions	524
19.5 Metabolomics: Metabolic Profile Elucidation	528
19.6 Integrating Genomic, Proteomic, and Metabolomic Tools to Accelerate Drug Development	530
19.7 Summary	532
<b>20 Pharmacoeconomics, Outcome, and Health Technology Assessment Research in Drug Development</b>	<b>535</b>
Abstract	535
20.1 Introduction: Health-Care Decisions and Health Outcomes	536
20.2 Integration of Pharmacoeconomic Outcome Research in Clinical Drug Development	538

20.3	Regional Differences in the Type of Evidence and Value Data Essential for Health-Care and Reimbursement Decisions	541
20.4	Biopharmaceutical Company Strategies	542
20.5	Summary	545
20.6	Acknowledgments	546

## **21 Future Prospects 547**

	Abstract	547
21.1	Progress and Benefits in Transforming Proteins and Genes into Biopharmaceuticals	548
21.2	Genomic Information Improves Safety and Production Cost of Biopharmaceuticals	548
21.3	The Business of Biopharmaceuticals and Economic Impacts	549
21.4	Influence of Biopharmaceuticals on Pharmaceutical Research, Development, and the Drug Industry	549
21.5	Public–Private Partnership in Financial and Regulatory Support to Improve Translational Success	550
21.6	Biopharmaceuticals and Public Health Benefits	551
21.7	Public Participation and Influence on Biopharmaceutical Development	551
21.8	Outlook	552

## **Appendix I. Dosage Form, Pharmacokinetics, and Disposition Data 555**

## **Appendix II. Molecular Characteristics and Therapeutic Use 581**

## **Appendix III. Nomenclature of Biotechnology Products 617**

## **Appendix IV. Other Information 621**

## **Index 633**

**Color plate section is located between pages 210 and 211.**